Emcure Pharmaceuticals has announced significant changes to its Board of Directors. Mr. Berjis Desai will be stepping down as Chairman and Director at the conclusion of the upcoming Annual General Meeting (AGM). In his place, Mr. Satish Mehta, currently Managing Director & CEO, will assume the role of Chairman. The board has also appointed Mr. Raghu Kumar as an Additional Director (Non-Executive and Independent). These changes are effective from August 06, 2026, pending shareholder approval.
Emcure Pharmaceuticals Announces Key Board Appointments
Emcure Pharmaceuticals Limited has informed exchanges about pivotal changes within its leadership structure. The Board of Directors, following recommendations from the Nomination and Remuneration Committee, has approved the appointment of a new Chairman and an Additional Director. These decisions were made during a board meeting held on August 06, 2026.
Leadership Transition at the Helm
Mr. Berjis Desai, who has been serving as the Chairman and a Non-executive, Non-Independent Director, has expressed his unwillingness to seek re-appointment at the ensuing Annual General Meeting (AGM). This decision stems from his appointment as a member of the National Commission for Minorities. Consequently, Mr. Desai will cease to hold his positions as Chairman and Director, effective from the conclusion of the AGM. The company has not specified the exact date of the AGM but indicates it is the upcoming one.
In light of Mr. Desai’s departure from the Chairmanship, the board has appointed Mr. Satish Mehta, the current Managing Director & CEO, to the role of Chairman. This transition will also take effect from the conclusion of the ensuing AGM.
Strengthening the Board with New Expertise
Further bolstering its directorship, Emcure Pharmaceuticals has appointed Mr. Raghu Kumar (DIN: 01983106) as an Additional Director. He will serve as a Non-Executive and Independent Director, with his appointment effective from August 06, 2026. Mr. Kumar’s tenure as an Independent Director will be for an initial term of three consecutive years, also commencing from August 06, 2026, subject to the approval of the company’s members at the AGM.
Mr. Raghu Kumar brings extensive experience, with over four decades in the pharmaceutical and healthcare sectors. He has held senior leadership roles in multinational organizations such as Allergan, Novartis, and Bayer. He also currently serves as the Chairman and Independent Director of Emcutix Biopharmaceuticals Limited, a subsidiary of Emcure. Mr. Kumar holds a Bachelor’s Degree in Economics and Mathematics and a Post Graduate Degree in Business Management (Marketing).
Disclosure Compliance
The company has provided detailed disclosures as required under Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlining the reasons for the changes and the profiles of the appointed directors. Mr. Raghu Kumar is confirmed not to be related to any existing Director or Key Managerial Personnel of Emcure Pharmaceuticals. Mr. Satish Mehta’s father, Mr. Samit Mehta and Mrs. Namita Thapar are Whole-time Directors of the company.
Source: BSE
